Compare Pfizer Inc (PFE) vs Workiva Inc (WK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Workiva Inc — how do they compare? Pfizer Inc trades at $27.77 (market cap $159.59B), while Workiva Inc trades at $75.4 (market cap $3.89B). The key difference: Pfizer Inc is far larger — about 41× Workiva Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Workiva Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Workiva Inc for 21 Days on average.
| PFE | WK | |
|---|---|---|
Market Cap | $159.59B | $3.89B |
Volume | 30,937,010 | 1,378,359 |
Sector | Health | Technology |
52-Week High | $29.02 | $93.31 |
52-Week Low | $23.67 | $44.31 |
Typical Hold Time | 158 Days | 21 Days |
Enterprise Value | $211.09B | $3.87B |
Dividend Yield | 6.14% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Workiva (WK) trades at $71.53, up 1.95% with a bullish technical signal supported by moving averages. The company shows strong revenue growth with 2026 revenue reaching $966 million and net income turning positive at $47 million. Recent earnings beats and AI product innovations at Amplify 2026 conference highlight operational momentum. Analyst consensus remains strongly bullish with 16 buy ratings and an $86 price target representing 20% upside potential from current levels.
The outlook remains positive with continued earnings growth and AI-driven product expansion driving potential upside. Key risks include high valuation multiples (P/E 85.15) and competitive pressures in the regulatory technology space. The stock's technical positioning near support at $71 suggests near-term stability, while fundamental improvements support longer-term growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Workiva Inc
Workiva is a leading provider of cloud-based platforms for complex reporting and compliance. It enables organizations to connect and manage data across financial reporting, ESG (Environmental, Social, and Governance), and GRC (Governance, Risk, and Compliance), serving as a single source of truth for auditable, transparent disclosures to regulators and stakeholders.
Read more on WK →
